Dr Reddy’s Plans to Launch Generic Semaglutide in 87 Countries

Dr Reddy’s Laboratories Ltd. plans to launch generic semaglutide — the active ingredient in Novo Nordisk A/S’s blockbuster weight loss drug Wegovy — in 87 countries next year as patents for the drug start expiring globally, CEO Erez Israeli told reporters in a post-earnings briefing.

• Dr Reddy’s will focus on core markets like Canada, Brazil and India, 2026 onwards
  • Also plans to launch the generic drug in countries where Novo does not have a patent
• “The semaglutide launch is very important” and co. has started filing for regulatory approvals in these countries: Israeli
• Semaglutide will be the first GLP-1 ...